GPCR250117C32500
- 0.43
- 0.000.00%
Structure Therapeutics Newsroom
H.C. Wainwright Initiates Structure Therapeutics(GPCR.US) With Buy Rating, Announces Target Price $80
JMP Securities Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $91
Promising Potential of Structure Therapeutics' ACCG-2671 Drives Buy Rating
Buy Rating for Structure Therapeutics, Inc. Driven by Innovative Drug Development and Promising Obesity Treatment Platform
Structure Therapeutics Price Target Maintained With a $80.00/Share by HC Wainwright & Co.
Piper Sandler Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $93
Structure Therapeutics, Inc. Sponsored ADR (GPCR) Gets a Buy From Piper Sandler
Structure Therapeutics Analyst Ratings
Jefferies Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $79
JMP Securities Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $91
JMP Securities Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Raises Target Price to $91
Buy Rating on Structure Therapeutics: Promising Developments in GPCR's Oral Amylin-Based Drug and Broad Obesity Treatment Pipeline
Analysts Offer Insights on Healthcare Companies: Artelo Biosciences (ARTL) and Structure Therapeutics, Inc. Sponsored ADR (GPCR)
HC Wainwright & Co. Initiates Coverage On Structure Therapeutics With Buy Rating, Announces Price Target of $80
Structure Therapeutics Analyst Ratings
Morgan Stanley Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $118
Jefferies Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $79
BMO Capital Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $100
Piper Sandler Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $93
Piper Sandler Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $93